Eugen Trinka1,2,3, Elinor Ben-Menachem4, Pedro A Kowacs5, Christian Elger6, Birgit Keller7, Kurt Löffler7, José Francisco Rocha8, Patrício Soares-da-Silva8,9,10. 1. Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University Salzburg, Salzburg, Austria. 2. Center for Cognitive Neuroscience, Salzburg, Austria. 3. Department of Public Health and Health Technology Assessment, University for Health Sciences, Medical Informatics, and Technology, Hall in Tirol, Austria. 4. Institute for Clinical Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 5. Neurological Institute of Curitiba, Curitiba, Brazil. 6. Department of Epileptology, University of Bonn, Bonn, Germany. 7. Accovion/Clinipace Worldwide, Eschborn, Germany. 8. Department of Research and Development, BIAL-Portela & Ca S.A., S. Mamede do Coronado, Portugal. 9. Pharmacology and Therapeutics Unit, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal. 10. MedInUP, Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal.
Abstract
OBJECTIVE: We assessed the efficacy and safety of once-daily eslicarbazepine acetate in comparison with twice-daily (BID) controlled-release carbamazepine (carbamazepine-CR) monotherapy in newly diagnosed focal epilepsy patients. METHODS: This randomized, double-blind, noninferiority trial (NCT01162460) utilized a stepwise design with 3 dose levels. Patients who remained seizure-free for the 26-week evaluation period (level A: eslicarbazepine acetate 800 mg/carbamazepine-CR 200 mg BID) entered a 6-month maintenance period. If a seizure occurred during the evaluation period, patients were titrated to the next target level (level B: eslicarbazepine acetate 1200 mg/carbamazepine-CR 400 mg BID, level C: eslicarbazepine acetate 1600 mg/carbamazepine-CR 600 mg BID) and the evaluation period began again. The primary endpoint was the proportion of seizure-free patients for 6 months after stabilization in the per protocol set. The predefined noninferiority criteria were -12% absolute and -20% relative difference between treatment groups. RESULTS:Eight hundred fifteen patients were randomly assigned; 785 (388 in theeslicarbazepine acetategroup and 397 in the carbamazepine-CR group) were included in the per protocol set, and 813 (401 in theeslicarbazepine acetate group and 412 in the carbamazepine-CR group) were included in the full analysis set for the primary analysis. Overall, 71.1% of eslicarbazepine acetate-treated patients and 75.6% of carbamazepine-CR-treated patients were seizure-free for ≥6 months at the last evaluated dose (average risk difference = -4.28%, 95% confidence interval [CI] = -10.30 to 1.74; relative risk difference = -5.87%, 95% CI = -13.50 to 2.44) in the per protocol set. Rates of treatment-emergent adverse events were similar between groups for patients in the safety set. Noninferiority was also demonstrated in the full analysis set, as 70.8% of patients with eslicarbazepine acetate and 74.0% with carbamazepine-CR were seizure-free at the last evaluated dose (average risk difference = -3.07, 95% CI = -9.04 to 2.89). SIGNIFICANCE: Treatment with eslicarbazepine acetate was noninferior to BID carbamazepine-CR. With its once-daily formulation, eslicarbazepine acetate provides a useful option for first-line monotherapy for adults with newly diagnosed epilepsy and focal onset seizures.
RCT Entities:
OBJECTIVE: We assessed the efficacy and safety of once-daily eslicarbazepine acetate in comparison with twice-daily (BID) controlled-release carbamazepine (carbamazepine-CR) monotherapy in newly diagnosed focal epilepsypatients. METHODS: This randomized, double-blind, noninferiority trial (NCT01162460) utilized a stepwise design with 3 dose levels. Patients who remained seizure-free for the 26-week evaluation period (level A: eslicarbazepine acetate 800 mg/carbamazepine-CR 200 mg BID) entered a 6-month maintenance period. If a seizure occurred during the evaluation period, patients were titrated to the next target level (level B: eslicarbazepine acetate 1200 mg/carbamazepine-CR 400 mg BID, level C: eslicarbazepine acetate 1600 mg/carbamazepine-CR 600 mg BID) and the evaluation period began again. The primary endpoint was the proportion of seizure-freepatients for 6 months after stabilization in the per protocol set. The predefined noninferiority criteria were -12% absolute and -20% relative difference between treatment groups. RESULTS: Eight hundred fifteen patients were randomly assigned; 785 (388 in the eslicarbazepine acetate group and 397 in the carbamazepine-CR group) were included in the per protocol set, and 813 (401 in the eslicarbazepine acetate group and 412 in the carbamazepine-CR group) were included in the full analysis set for the primary analysis. Overall, 71.1% of eslicarbazepine acetate-treated patients and 75.6% of carbamazepine-CR-treated patients were seizure-free for ≥6 months at the last evaluated dose (average risk difference = -4.28%, 95% confidence interval [CI] = -10.30 to 1.74; relative risk difference = -5.87%, 95% CI = -13.50 to 2.44) in the per protocol set. Rates of treatment-emergent adverse events were similar between groups for patients in the safety set. Noninferiority was also demonstrated in the full analysis set, as 70.8% of patients with eslicarbazepine acetate and 74.0% with carbamazepine-CR were seizure-free at the last evaluated dose (average risk difference = -3.07, 95% CI = -9.04 to 2.89). SIGNIFICANCE: Treatment with eslicarbazepine acetate was noninferior to BIDcarbamazepine-CR. With its once-daily formulation, eslicarbazepine acetate provides a useful option for first-line monotherapy for adults with newly diagnosed epilepsy and focal onset seizures.
Authors: Jacqueline A French; Andrew J Cole; Edward Faught; William H Theodore; Annamaria Vezzani; Kore Liow; Jonathan J Halford; Robert Armstrong; Jerzy P Szaflarski; Sarah Hubbard; Jagdish Patel; Kun Chen; Wei Feng; Marco Rizzo; Jacob Elkins; Gabrielle Knafler; Kimberly A Parkerson Journal: Neurology Date: 2021-09-14 Impact factor: 9.910
Authors: Robert T Wechsler; Rodney A Radtke; Michael Smith; David G Vossler; Laura Strom; Eugen Trinka; Hailong Cheng; Todd Grinnell; David Blum; Mariana Vieira; Joana Moreira; Francisco Rocha Journal: Epilepsia Date: 2019-07-01 Impact factor: 5.864
Authors: Darshan Mehta; Matthew Davis; Andrew J Epstein; Brian Wensel; Todd Grinnell; G Rhys Williams Journal: Clinicoecon Outcomes Res Date: 2021-04-19
Authors: Elinor Ben-Menachem; Hans Peter Grebe; Kiyohito Terada; Lori Jensen; Ting Li; Marc De Backer; Björn Steiniger-Brach; Teresa Gasalla; Melissa Brock; Victor Biton Journal: Epilepsia Date: 2019-11-21 Impact factor: 5.864
Authors: Scott Mintzer; Svetlana Dimova; Ying Zhang; Björn Steiniger-Brach; Marc De Backer; Daya Chellun; Robert Roebling Journal: Epilepsia Date: 2020-11-17 Impact factor: 5.864